AGAVE-201, A Phase 2, Open-label, Randomized, MulticenterStudy to Evaluate the Efficacy, Safety and Tolerability ofAxatilimab at 3 Different Doses in Patients with Recurrent orRefractory Active Chronic Graft Versus Host Disease who haveReceived at le

Holtan, Shernan G (PI)
Arora, Mukta (Prior Principal Investigator)

Medicine - Hematology, Oncology, Transplant

Project: Research project

Description

AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at le

Status	Active
Effective start/end date	11/1/20 → 10/31/25

Funding

SYNDAX PHARMACEUTICALS

AGAVE-201, A Phase 2, Open-label, Randomized, MulticenterStudy to Evaluate the Efficacy, Safety and Tolerability ofAxatilimab at 3 Different Doses in Patients with Recurrent orRefractory Active Chronic Graft Versus Host Disease who haveReceived at le

Project Details

Description

Funding

Fingerprint